Levodopa, vitamins, ageing and the neuropathy of Parkinson's disease

Journal of Neurology

Volumn 260, Issue 11, 2013, Pages 2844-2848

  Rajabally, Yusuf A ^a,b   Martey, Jean ^a  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Age; Folate; Levodopa; Levodopa na ve; Neuropathy; Parkinson's disease; Vitamin B12

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; LEVODOPA;

ADULT; AGE; AGING; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; FOLIC ACID BLOOD LEVEL; HUMAN; MALE; NEUROPATHY; PARKINSON DISEASE; PRIORITY JOURNAL;

ADULT; AGED; AGING; ANTIPARKINSON AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; FOLIC ACID; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; PARKINSON DISEASE; VITAMIN B 12;

EID: 84889574187     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-013-7079-8     Document Type: Article

References (18)

1. Toth C, Brown MS, Furtado S, Suchowersky O, Zochodne D (2008) Neuropathy as a potential complication of levodopa use in Parkinson's disease. Mov Disord 23:1850-1859
2. Toth C, Breithaupt K, Ge S et al (2010) Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson's disease. Ann Neurol 67:28-36
3. Rajabally YA, Martey J (2011) Neuropathy in Parkinson disease. Prevalence and determinants. Neurology 77:1947-1950
4. Singleton JR, Bixby B, Russell JW et al (2008) The Utah early neuropathy scale: a sensitive clinical scale for early sensory predominant neuropathy. J Peripher Nerv Syst 13:218-227
5. England JD, Gronseth GS, Franklin G, American Academy of Neurology et al (2009) Practice parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American academy of neurology, American association of neuromuscular and electrodiagnostic medicine, and American academy of physical medicine and rehabilitation. Neurology 72:185-192
6. Rampersaud G, Kauwell GP, Bailey LB (2003) Folate: a key to optimizing health and reducing disease risk in the elderly. J Am Coll Nutr 22:1-8
7. 12 status in relation to cognitive impairment and anaemia in the setting of voluntary fortification in the UK. Br J Nutr 100:1054-1059
8. Rösche J, Uhlmann C, Fröscher W (2003) Low serum folate levels as a risk factor for depressive mood in patients with chronic epilepsy. J Neuropsychiatry Clin Neurosci 15:64-66
9. 12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification. Am J Clin Nutr 85:193-200
10. Taskforce of the Movement Disorder Society (2002) Management of Parkinson's disease: an evidence-based review. Levodopa. Mov Disord 17(S4):S23-S37
11. 12 and folic acid in a population-based sample of adults between 35 and 80 years of age. Public Health Nutr 5:505-511
12. Manzoor M, Runcie J (1976) Folate-responsive neuropathy: report of 10 cases. Br Med J 1:1176-1178
13. Botez MI, Peyronnard JM, Bachevalier J, Charron L (1978) Polyneuropathy and folate deficiency. Arch Neurol 35:581-584
14. Parry TE (1994) Folate responsive neuropathy. Presse Med 23:131-137
15. Koike H, Takahashi M, Ohyama K, Hashimoto R, Kawagashira Y, Iijima M, Sobue G (2013) The significance of folate deficiency in peripheral neuropathy. Abstract meeting of the peripheral nerve society. J Peripher Nerv Syst 18S2:57
16. Müller T, Renger K, Kuhn W (2004) Levodopa-associated increase in homocysteine levels and sural axonal degeneration. Arch Neurol 61:657-660
17. Ceravolo R, Cossu G, Bandettini di Poggio M et al (2013) Neuropathy and Levodopa in Parkinson's disease: evidence from a multicentre study. Mov Disord [E-Pub ahead of print]
18. Montastruc JL, Danton AC, Durrieu G, French Association of Regional Pharmocovigilance Centres et al (2010) Neuropathy as a potential complication of levodopa use in Parkinson's disease: a pharmacological and pharmacovigilance point of view. Mov Disord 25:660-661